Abiy D. Woldetsadik, Ph.D., earned his M.S. in biotechnology, molecular targeting and drug discovery at Johns Hopkins University in 2009. He then earned his Ph.D. in molecular nanomedicine at the University of Eastern Piedmont in March 2014. While a doctoral student, he designed and developed a nanoparticle vaccine delivery system to induce antigen-specific immune tolerance on Experimental Autoimmune Encephalomyelitis (EAE) mice model of multiple sclerosis. He spent one year as a visiting scholar at the University of New Mexico Center for Biomedical Engineering where he designed and developed multiplex biomimetic assays, cell-free protein expression systems for transmembrane proteins, as well as nanoparticles. In 2013, he joined New York University as a postdoctoral researcher to study and design tumor-targeted therapeutic peptides, targeted drug delivery systems, biochemical and biophysical characterization of drug candidates as well as scaffold design for bone tissue engineering applications. In 2017, Dr. Woldetsadik was recruited to Southern Research by the late Janet Houghton, where he is currently working in the lab of Rebecca Boohaker. Dr. Woldetsadik’s main research focus is to discover novel anti-cancer drugs with a focus on pancreatic cancer. Specifically, he aims to determine the critical role of the transcription factor GLI in survival of pancreatic cancer cells.